The Latest Breaking News from Omicron

Eris desends from Omicron and is now the second most prevalent Covid variant in the UK

Eris desends from Omicron and is now the second most prevalent Covid variant in the UK

Eris desends from Omicron and is now the second most prevalent Covid variant in the UK

The facts surrounding the Delta variant provide a cautionary tale of misinformation about SARS-CoV-2

Chulalongkorn University's Faculty of Medicine is recruiting volunteers to take part in a new study aimed at assessing the efficacy of the Moderna bivalent Covid-19 vaccine in protecting against new sub-variants of the Omicron virus and whether or not it should be recommended as an alternative booster shot in Thailand.

Five stories from The Conversation’s archives that helped illuminate complex issues at pivotal moments in the pandemic.

India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24.

So the California Court of Appeal has held, concluding that there is enough of a factual dispute (under California's plaintiff-friendly pleading standards) for the case to go forward.

In early 2021, recommendations about COVID vaccines were pretty straightforward – get two doses, as soon as you are eligible. A year later, we knew getting a third dose was important for protection against the new Omicron variant.

India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late on June 19. This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against…

The next round of COVID-19 vaccines will target one of the latest versions of the coronavirus